Physician profile
Reena N Jethva
NPI 1083857858
$2,901.76
in general payments reported to CMS, 2019-2025
8 companies · $2,593 in 2025
The $2,593 reported for 2025 was more than what a typical Clinical Genetics (M.D.) provider received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2022: $20.59 · 2024: $136 · 2025: $2,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,000 · Food and Beverage: $432 · Travel and Lodging: $262 · Education: $35.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,000.00 |
| Food and Beverage | $431.96 |
| Travel and Lodging | $261.54 |
| Education | $35.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ptc Therapeutics, INC. | $2,332.73 | 2025 | Sephience |
| Biomarin Pharmaceutical INC. | $228.70 | 2019-2024 | Palynziq |
| Ucb, INC. | $143.24 | 2025 | |
| Orchard Therapeutics North America | $116.85 | 2025 | Lenmeldy |
| Rhythm Pharmaceuticals, INC. | $32.71 | 2024 | |
| Genzyme Corporation | $20.59 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.77 | 2019 | |
| Shire North American Group INC | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Jethva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.